Pharsight

Drugs that contain Bedaquiline Fumarate

1. Sirturo patents expiration

SIRTURO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498343 JANSSEN THERAP Mycobacterial inhibitors
Dec, 2026

(2 years from now)

US8546428 JANSSEN THERAP Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-251) Aug 09, 2026
Orphan Drug Exclusivity(ODE-307) May 27, 2027
New Patient Population(NPP) Aug 09, 2022
Orphan Drug Exclusivity(ODE-38) Dec 28, 2019
New Chemical Entity Exclusivity(NCE) Dec 28, 2017
Orphan Drug Exclusivity(ODE) Dec 28, 2019

NCE-1 date: 28 December, 2016

Market Authorisation Date: 27 May, 2020

Treatment: Treatment of pulmonary multi-drug resistant tuberculosis

Dosage: TABLET;ORAL

More Information on Dosage

SIRTURO family patents

Family Patents